Breastfeeding and GLP-1 medicines

Why one answer for all GLP-1 medicines fails

Three things need checking for any medicine: how much passes into milk, how much a baby absorbs by mouth, and what safety data exist for infants. Limited milk-transfer data do not prove a treatment suits every breastfeeding parent and baby. A general warning written before newer evidence may also miss a later label change.

Check the current UK Summary of Product Characteristics and patient leaflet for the exact product you are prescribed. An injection and a tablet also differ in other ways, including the ingredients that help the tablet absorb. A familiar active ingredient is no reason to apply one product's breastfeeding advice to another.

The reason for treatment matters

The decision may differ when a medicine treats diabetes compared with weight management alone. Your clinical team weighs how important treatment is, what alternatives exist and what you and your baby need. Your baby's age, any prematurity, their health and how you feed all shape the discussion.

A good review brings in your prescriber and, where needed, a professional with expertise in breastfeeding medicine. Ask them what is known, what is still uncertain and how they will monitor any plan. A bare statement that a medicine is safe or unsafe, with no context, is not enough.

Get help with the decision

If you already take treatment and start breastfeeding, or you come across conflicting advice, contact your clinical team promptly. Give them the product name, formulation, dose and timing. Do not suddenly change necessary diabetes treatment without another plan in place.

Ask when the advice was last updated

Ask which label or specialist reference the advice relies on and when the reference was updated. This helps most when a pharmacy leaflet, an older MHRA overview and a newer product label seem to disagree. Your clinician should resolve the difference for you, so you are not left to pick between sources alone.

There is no single yes or no for the whole class of medicines. A blanket answer would hide real differences and go out of date as information changes. Your next step is a written decision for your own medicine, based on current evidence and your situation, with a named contact if feeding, symptoms or treatment needs change.

What current UK labels say

The UK Mounjaro SmPC, updated in September 2026, says tirzepatide may be considered during breastfeeding. The SmPC describes limited milk-transfer data and remaining uncertainty. The current oral Wegovy information says not to use the tablet during breastfeeding, partly because of its absorption-enhancing ingredient. Foundayo also advises against use while breastfeeding.

These differences show why one rule for the whole class does not work. They do not mean you decide alone. Your clinical team makes the individual decision and plans any alternative treatment.